Lingus schreef op 30 oktober 2018 19:55:
[...]
Uit
www.celyad.com/en/news/celyad-reports...Progress made in Colorectal Cancer (CRC)
THINK Trial
Fourteen solid cancer patients (one pancreas, two ovarian and eleven CRC) completed the three dose-levels evaluated in the dose escalation segment.
One dose-limiting toxicity (DLT) was reported at the highest dose-level (3x109) triggering the enrollment of three additional patients. No other DLT was reported in the three additional patients treated at the third dose level.
Preliminary results will be reported during the Society for Immunotherapy of Cancer (SITC) Annual Meeting (November 7-11, Washington).
Progress made in Acute Myeloid Leukemia (AML)
THINK Trial
Interim results demonstrate signs of clinical activity ranging from complete responses to stable diseases at lower doses in AML patients receiving one cycle of CYAD-01 per protocol.
Twelve patients[6] have been enrolled to date. Enrollment for the highest dose (3x109) is expected to be completed in September 2018.
A complete second cycle of investigational therapy was administered in the first AML patient enrolled into the second dose level (1x109). A second AML patient at the third dose level (3x109) has received the first injection of the second cycle. The second cycle is administered to determine the impact of the clinical benefit of additional CYAD-01 administrations. No dose-limiting toxicity has been observed to date.
The first ever reported complete response by an investigational CAR-T cell therapy without preconditioning in a patient with refractory and relapsed AML was published as a case study in Haematologica.
Preliminary results of the dose escalation segment will be reported in December during the American Society for Hematology (ASH) Annual Meeting (December 1-4, San Diego).